Related Experiment Video
Updated: Jul 11, 2026
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
Epirubicin for breast cancer during pregnancy: a case report
Padma Eedarapalli1, Nibedan Biswas, Matthew Coleman
1Department of Obstetrics and Gynaecology, Poole Hospital, NHS Trust, Longfleet Road, Poole BH 15 2JB, UK. padmakumari2003@yahoo.co.uk
Background:
The rarity of breast cancer in pregnancy and conflict between the optimal maternal therapy and fetal risks make its management challenging. Chemotherapy is the standard treatment for advanced cases. Epirubicin as a combination agent has been reported for breast and other cancers in pregnancy but not as a single agent. We report a case of advanced breast cancer treated with epirubicin neoadjuvant chemotherapy in pregnancy.
Case:
A 30-year-old primigravida with multifocal, grade 3 invasive ductal carcinoma, stage T2 N1M0, received 4 cycles of primary epirubicin chemotherapy in pregnancy from 23 weeks' gestation. The chemotherapy was well tolerated by the mother and fetus, and a good response was achieved prior to postnatal combination chemotherapy and definitive surgery.
Conclusion:
Epirubicin chemotherapy appears safe and effective in pregnancy.
